Narcolepsy (Neurological) — Disease Characteristics Research Report

Target disease

Narcolepsy is a chronic central disorder of hypersomnolence characterized by excessive daytime sleepiness (EDS) with rapid-eye-movement (REM) sleep dysregulation, and is currently classified into narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). NT1 is strongly linked to orexin/hypocretin deficiency and commonly includes cataplexy; NT2 lacks cataplexy and typically does not show orexin deficiency, with etiology less well established. (biscarini2025narcolepsyandrapid pages 1-2, xu2025acomprehensivereview pages 1-2)

Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

The retrieved full texts did not contain authoritative identifier mappings (ICD-10/ICD-11, MeSH, OMIM, Orphanet, MONDO). Therefore, these identifiers cannot be populated from the current evidence set and should be curated from dedicated terminologies (e.g., ICD/MeSH/MONDO/Orphanet) outside this tool run.

Common synonyms/alternate names

• Narcolepsy with cataplexy (historical; largely aligns with NT1) (ariascarrion2026narcolepsyasan pages 3-4)
• Narcolepsy without cataplexy (historical; overlaps NT2 and “borderland” phenotypes) (ariascarrion2026narcolepsyasan pages 3-4)
• Hypocretin/orexin-deficient narcolepsy (NT1 phenotype emphasis) (xu2025acomprehensivereview pages 1-2, mignot2002theroleof pages 5-6)

Source type note

This report integrates aggregated disease-level resources (reviews, cohorts, pharmacovigilance databases) and some patient-level evidence (e.g., clinical diagnostic criteria tables compiled in reviews). (baldini2024pediatricnarcolepsytype pages 1-2, zhou2024evaluationofpitolisant pages 1-2)

1. Disease information (current understanding)

Narcolepsy is now commonly conceptualized as a disorder of sleep–wake and REM-state boundary control. A modern “systems” view emphasizes multisystem consequences of hypothalamic orexin dysfunction rather than only the classic symptom pentad. (ariascarrion2026narcolepsyasan pages 2-3)

Direct abstract-supported definition/overview: A review of REM sleep and narcolepsy summarizes that narcolepsy is divided into NT1 and NT2, with key criteria relying on SOREMPs captured on polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT), and that NT1 mechanisms are partly elucidated through HLA association and orexin/hypocretin deficiency. (biscarini2025narcolepsyandrapid pages 1-2)

2. Etiology

2.1 Primary causal factors

NT1: orexin neuron loss with strong immune association

NT1 is linked to selective loss/dysfunction of hypothalamic orexin-producing neurons and is increasingly supported as an immune-mediated disease in genetically predisposed individuals. (xu2025acomprehensivereview pages 1-2, ariascarrion2026narcolepsyasan pages 5-6)

A narrative review of T-cell involvement states that NT1 can be understood via interplay of genetic predisposition (notably HLA-DQB1*06:02), environmental triggers (e.g., H1N1 infection/vaccination), and immune mechanisms leading to hypocretin neuronal loss. (xu2024theroleof pages 1-2)

NT2: heterogeneous/less defined

NT2 typically lacks cataplexy and orexin deficiency; its causes remain less well defined. However, subgroups with intermediate orexin levels may overlap immunogenetically with NT1. (biscarini2025narcolepsyandrapid pages 1-2, hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 3-3)

2.2 Risk factors

Genetic risk factors

• HLA-DQB1*06:02 / extended haplotypes: In a Swedish cohort, NT1 showed strong association with DRB501:01:01–DRB115:01:01–DQA101:02:01–DQB106:02:01 (OR 7.01, 95% CI 3.97–12.37) and additional genotype combinations reaching OR 23.61 (95% CI 4.48–110.76). (hamdan2024high‐resolutionhlasequencing pages 4-5)
• HLA frequency enrichment: A 2024 review notes DQB1*06:02 is present in ~98% of NT1 with cataplexy vs ~25% of the general population, and that homozygosity increases risk vs heterozygosity. (xu2024theroleof pages 2-3)
• Non-HLA immune loci: Reported susceptibility loci include TRA (T-cell receptor alpha locus), CTSH, PPAN, P2RY11, IL10RB, and CPT1B, consistent with immune and T-cell biology. (xu2024theroleof pages 3-5, xu2024theroleof pages 2-3)

Environmental/infectious and vaccine-associated risk factors

• Influenza A/H1N1 infection and AS03-adjuvanted Pandemrix vaccination (2009–2010) are repeatedly highlighted as environmental triggers linked to increased NT1 incidence in specific settings. (xu2024theroleof pages 1-2, xu2024theroleof pages 3-5, ariascarrion2026narcolepsyasan pages 5-6)

2.3 Protective factors

The retrieved evidence did not provide clearly defined protective genetic variants or modifiable environmental protective factors for narcolepsy in a way that can be summarized with specificity.

2.4 Gene–environment interaction (G×E)

The most consistent G×E framework in the retrieved literature is HLA-driven antigen presentation + environmental priming (H1N1 infection/vaccination) leading to T-cell activation and ultimately selective injury of orexin neurons. (xu2024theroleof pages 1-2, xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6)

3. Phenotypes (clinical features)

3.1 Core phenotypes (symptoms/signs)

Classic symptom cluster often includes EDS, cataplexy (NT1), disrupted nighttime sleep, sleep paralysis, and hypnagogic/hypnopompic hallucinations. Pediatric NT1 reviews explicitly enumerate these as core symptoms. (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 2-4)

Pediatric-specific presentation nuances * EDS may be “masked” by hyperactivity/irritability and may be misdiagnosed as ADHD. (baldini2024pediatricnarcolepsytype pages 2-4) * Cataplexy in children may have atypical semiology (“cataplectic facies” with facial hypotonia/ptosis and mixed hyperactive movements). (baldini2024pediatricnarcolepsytype pages 2-4)

3.2 Frequency, onset, progression (where available)

• Disturbed nighttime sleep (DNS) frequency in pediatric NT1: 53–78%. (baldini2024pediatricnarcolepsytype pages 2-4)
• RBD in young patients with NT1: NT1 reported as leading cause of RBD in young patients (up to 60%). (baldini2024pediatricnarcolepsytype pages 2-4)
• Diagnostic/phenotype proportions in a spectrum framing: A review proposes proportions such as “typical cataplexy and all biological markers” 50–80%, with additional borderland groups. (ariascarrion2026narcolepsyasan pages 2-3)

3.3 Quality-of-life impact

A pediatric state-of-the-art review emphasizes that NT1 impairs children’s quality of life and supports early diagnosis and multidisciplinary management, including behavioral and psychosocial interventions. (baldini2024pediatricnarcolepsytype pages 1-2)

3.4 Suggested HPO terms (non-exhaustive, mapping suggestions)

The retrieved sources support the following phenotype constructs; HPO codes should be verified in an ontology browser: * Excessive daytime sleepiness (EDS) (baldini2024pediatricnarcolepsytype pages 2-4) * Cataplexy (baldini2024pediatricnarcolepsytype pages 2-4) * Sleep paralysis (baldini2024pediatricnarcolepsytype pages 1-2) * Hypnagogic/hypnopompic hallucinations (baldini2024pediatricnarcolepsytype pages 1-2) * Fragmented sleep / disturbed nighttime sleep (baldini2024pediatricnarcolepsytype pages 2-4) * REM sleep behavior disorder (baldini2024pediatricnarcolepsytype pages 2-4) * Rapid weight gain/obesity (pediatric onset-associated) (biscarini2025narcolepsyandrapid pages 5-6) * Precocious puberty (pediatric onset-associated) (biscarini2025narcolepsyandrapid pages 5-6)

4. Genetic / molecular information

4.1 Causal genes

For idiopathic NT1, the dominant genetic signal is polygenic (not a single Mendelian “causal gene”). However, a REM-sleep/narcolepsy review notes that a canine model identified mutations in the orexin receptor 2 pathway (historically important to orexin biology). (biscarini2025narcolepsyandrapid pages 1-2)

4.2 Susceptibility loci (selected)

• HLA class II region including DQB1*06:02 and extended haplotypes (hamdan2024high‐resolutionhlasequencing pages 4-5, xu2024theroleof pages 2-3)
• TRA locus (TCR alpha chain) (xu2024theroleof pages 2-3)
• Additional loci reported in a 2024 T-cell narrative review: CTSH rs34593439, PPAN rs1551570, P2RY11 rs2305795, IL10RB rs2834188, CPT1B rs5770917 (xu2024theroleof pages 3-5)

4.3 Biomarkers

CSF hypocretin-1 (orexin-A)

A landmark diagnostic study defined CSF hypocretin-1 ≤110 pg/mL as a best-performing diagnostic cutoff (with >200 pg/mL considered normal), and in “typical cataplexy” reported sensitivity 87% and specificity 99%. (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9)

Autoantibodies

A 2024 high-resolution HLA/autoantibody study found no difference in anti-HCRTR2 autoantibody levels across NT1, NT2, idiopathic hypersomnia, and general population controls (p=.8524), suggesting hypocretin receptor 2 is unlikely to be a major autoimmune target in these cohorts. (hamdan2024high‐resolutionhlasequencing pages 1-2, hamdan2024high‐resolutionhlasequencing pages 6-6)

4.4 Epigenetics / omics

The retrieved evidence notes that epigenetic alterations have been reported (e.g., within immune loci), but does not provide specific methylation loci or standardized effect sizes in the excerpts available here. (xu2024theroleof pages 14-15, ariascarrion2026narcolepsyasan pages 7-8)

5. Mechanism / pathophysiology

5.1 Causal chain (NT1; synthesis)

1) Genetic susceptibility: strong HLA class II association (e.g., DQB106:02) and additional immune/TCR loci (xu2024theroleof pages 2-3, hamdan2024high‐resolutionhlasequencing pages 4-5) 2) Environmental priming: H1N1 influenza infection and/or Pandemrix vaccination in specific outbreaks (xu2024theroleof pages 1-2, xu2024theroleof pages 3-5) 3) Immune activation and autoimmunity: evidence supports autoreactive CD4+ and CD8+ T cells targeting orexin-related antigens; molecular mimicry is plausible but not fully resolved across studies (xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6) 4) Selective orexin neuron loss/dysfunction: substantial neuron loss has been estimated (75–95% loss in NT1 described in a systems review) (ariascarrion2026narcolepsyasan pages 5-6) 5) Network-level consequences*: destabilized wake maintenance and REM boundary control producing EDS, SOREMPs, cataplexy, hallucinations, and sleep paralysis (xu2025acomprehensivereview pages 9-11, biscarini2025narcolepsyandrapid pages 1-2)

5.2 Cell types (CL suggestions) and biological processes (GO suggestions)

Evidence supports immune effector involvement and hypothalamic neuron injury: * CL terms (suggested): CD4-positive T cell; CD8-positive T cell; hypothalamic orexin neuron; histaminergic neuron (TMN) (TAK-861 depolarizes TMN histaminergic neurons via OX2R) (xu2024theroleof pages 7-8, mitsukawa2024tak861apotent pages 2-3) * GO biological processes (suggested): antigen processing and presentation (MHC class II); T cell activation; IFN-γ–mediated signaling and MHC I upregulation; regulation of sleep–wake cycle; regulation of REM sleep (xu2024theroleof pages 7-8, biscarini2025narcolepsyandrapid pages 1-2)

5.3 Anatomical localization (UBERON suggestions)

• Lateral hypothalamic area (orexin neuron field) (ariascarrion2026narcolepsyasan pages 3-4)
• Hypothalamus (disease framing as hypothalamic encephalopathy) (ariascarrion2026narcolepsyasan pages 2-3)

6. Epidemiology, inheritance, and population

6.1 Prevalence/incidence (selected values present in retrieved sources)

• A treatment review describes NT1 prevalence as approximately ~1 in 2000. (xu2025acomprehensivereview pages 1-2)
• A systems review summarizes examples of claims/survey-based estimates (not a primary epidemiology study): U.S. prevalence 37.7/100,000 and incidence 2.6/100,000 person-years; Japan claims prevalence ~37.5/100,000 and incidence 5.1/100,000 person-years, with substantial geographic variation and diagnostic uncertainty (notably for NT2). (ariascarrion2026narcolepsyasan pages 3-4)

6.2 Inheritance pattern

The evidence supports narcolepsy (especially NT1) as multifactorial/polygenic with strong HLA association rather than Mendelian inheritance. (xu2024theroleof pages 2-3, xu2024theroleof pages 3-5)

6.3 Demographics and heterogeneity

Pediatric narcolepsy is emphasized as frequently beginning in childhood/adolescence, and pediatric phenotype has distinctive features (e.g., weight gain and atypical cataplexy semiology). (biscarini2025narcolepsyandrapid pages 5-6, baldini2024pediatricnarcolepsytype pages 2-4)

7. Diagnostics

7.1 Standard diagnostic criteria (ICSD-3-TR, 2023)

The pediatric NT1 review reproduces ICSD-3-TR (2023) diagnostic criteria for NT1 and NT2, including EDS duration, MSLT requirements (mean sleep latency ≤8 min and ≥2 SOREMPs), cataplexy status, and CSF hypocretin thresholds, and illustrates the ICSD-3-TR change that allows nocturnal PSG SOREMP + cataplexy to suffice for NT1 diagnosis even if MSLT is not definitive. (baldini2024pediatricnarcolepsytype media 3ad4bd72, baldini2024pediatricnarcolepsytype pages 8-9)

7.2 Core tests

• Overnight PSG + MSLT remain key objective tests, anchored on SOREMP detection. (biscarini2025narcolepsyandrapid pages 1-2)
• CSF hypocretin-1 is described as the strongest biomarker in reviews and has robust test characteristics in foundational work. (ariascarrion2026narcolepsyasan pages 21-22, mignot2002theroleof pages 5-6)

7.3 Test performance and pediatric considerations

• Nocturnal SOREMP in pediatrics: reported specificity 97.3% and sensitivity 54.8% (reviewed pediatric data). (baldini2024pediatricnarcolepsytype pages 8-9)
• CSF hypocretin: ≤110 pg/mL cutoff with high specificity and good sensitivity for typical cataplexy. (mignot2002theroleof pages 5-6, mignot2002theroleof pages 8-9)

7.4 Differential diagnosis highlights (from pediatric review excerpts)

Diagnostic workup emphasizes excluding insufficient sleep and circadian disorders (actigraphy 7–10 days), and distinguishing NT2 from idiopathic hypersomnia (IH) via SOREMP patterns and/or total sleep time. (baldini2024pediatricnarcolepsytype pages 9-11)

8. Treatment (current applications and real-world implementation)

8.1 Symptomatic pharmacotherapy (current standard)

A synthesis review rates modafinil/armodafinil, solriamfetol, pitolisant, and sodium oxybate formulations as high-certainty, strong-recommendation symptomatic treatments. (ariascarrion2026narcolepsyasan pages 21-22)

Pediatric regulatory status and practice A pediatric NT1 review notes: * No approvals under age 6. * Sodium oxybate is approved by FDA and EMA for ages ≥7. * EMA approved pitolisant in 2023 for patients >6 years with or without cataplexy. (baldini2024pediatricnarcolepsytype pages 11-13)

8.2 Oxybate dosing innovations (real-world implementation)

RESTORE (2024) evaluated switching from twice-nightly immediate-release oxybate to once-nightly extended-release sodium oxybate: * 93.9% (92/98) preferred once-nightly dosing. * Prior to switching, 69.2% had missed the second dose at least once; nocturnal mobility after the second dose was common, with reported falls and injuries. * After switching, 91.2% felt better able to follow the recommended dosing schedule. These data emphasize adherence/safety burdens of middle-of-the-night redosing and a real-world rationale for simplified regimens. (roy2024restoreoncenightlyoxybate pages 1-2, roy2024restoreoncenightlyoxybate pages 2-3)

8.3 Mechanism-based “orexin restoration” therapeutics (recent developments)

A major 2023–2024 development area is small-molecule OX2R agonists designed to replace deficient orexin signaling.

Preclinical evidence (2024): TAK-861 (oveporexton) A 2024 Scientific Reports study characterized TAK-861 as an oral OX2R-selective agonist with OX2R EC50 2.5 nM and ~3,000-fold selectivity over OX1R. It promoted wakefulness in mice and monkeys (minimum effective dose 1 mg/kg) and improved narcolepsy-like phenotypes in NT1 mouse models (orexin/ataxin-3 and orexin-tTA;TetO DTA), including reduced wake fragmentation and reduced cataplexy-like episodes. (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 3-4, mitsukawa2024tak861apotent pages 2-3, mitsukawa2024tak861apotent pages 10-11)

Clinical development (trial registry; real-world implementation horizon) Multiple trials are registered for orexin agonists including TAK-861 and danavorexton (TAK-925). Examples include completed and recruiting studies spanning Phase 1–3 (e.g., NCT05687903 Phase 2; Phase 3 trials listed for TAK-861; TAK-925 Phase 1 programs). (xu2025acomprehensivereview pages 9-11)

8.4 Safety signals and pharmacovigilance (recent data)

A 2024 FAERS analysis (2019–2023) identified signal counts: 50 signals/762 cases for pitolisant, 640/46,962 for sodium oxybate, 40/1,228 for solriamfetol, and 72/632 for modafinil. Psychiatric and nervous system disorders predominated; sodium oxybate showed strong respiratory-related signals (e.g., sleep apnea syndrome n=1326 with high disproportionality metrics) and hypertension signals. These are signal-detection outputs without denominators and cannot be interpreted as incidence rates, but they inform monitoring priorities. (zhou2024evaluationofpitolisant pages 1-2, zhou2024evaluationofpitolisant pages 8-9)

8.5 Suggested MAXO terms (treatment action ontology; mapping suggestions)

Based on interventions discussed: * Pharmacotherapy for hypersomnolence / wake promotion (modafinil/armodafinil/solriamfetol/pitolisant) (ariascarrion2026narcolepsyasan pages 21-22) * Oxybate therapy (sodium oxybate; low-sodium oxybate; once-nightly formulations) (roy2024restoreoncenightlyoxybate pages 1-2, baldini2024pediatricnarcolepsytype pages 11-13) * Orexin receptor agonist therapy (OX2R agonists) (mitsukawa2024tak861apotent pages 1-2) * Behavioral sleep intervention (planned naps, sleep hygiene, school programs) (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 11-13)

9. Prevention

9.1 Primary prevention

No established primary prevention strategy exists for idiopathic NT1/NT2.

9.2 Secondary/tertiary prevention (complication reduction)

Evidence supports early diagnosis and multidisciplinary management in pediatrics to reduce educational/psychosocial impact, plus careful monitoring for comorbidities (metabolic/endocrine, psychiatric) and medication adverse effects. (baldini2024pediatricnarcolepsytype pages 1-2, baldini2024pediatricnarcolepsytype pages 14-15)

9.3 Vaccine-related considerations

Pandemrix-associated risk signals are part of the etiologic history in some countries, but causality and generalization to modern vaccines are complex; a recent immunology-focused narrative emphasizes that mechanistic mimicry is plausible but incompletely resolved and that findings vary across studies. (xu2024theroleof pages 7-8, ariascarrion2026narcolepsyasan pages 5-6)

10. Other species / natural disease and model organisms

10.1 Model organisms used in current research

The orexin system has strong translational animal models. A 2024 preclinical therapeutic paper uses: * orexin/ataxin-3 mice (orexin neuron degeneration model) * orexin-tTA;TetO DTA mice (conditional orexin neuron ablation) These models support evaluation of orexin-pathway therapeutics for wake consolidation and cataplexy-like behaviors. (mitsukawa2024tak861apotent pages 1-2, mitsukawa2024tak861apotent pages 10-11)

10.2 Model limitations

The retrieved evidence emphasizes that models typically capture fragments of the human phenotype (e.g., cataplexy-like episodes, fragmentation) and are most directly aligned with NT1 biology rather than NT2 heterogeneity. (mitsukawa2024tak861apotent pages 1-2, biscarini2025narcolepsyandrapid pages 1-2)

11. Key recent evidence summary table

The following table consolidates the most actionable recent and foundational evidence captured in this tool run.

Table: This table compiles high-yield recent and foundational evidence for narcolepsy across diagnosis, biomarkers, immunogenetics, therapeutics, and real-world safety. It is useful as a quick-reference summary for a disease knowledge base entry.

12. Notes on evidence gaps and curation requirements

• Disease identifiers (ICD/MeSH/MONDO/OMIM/Orphanet): not present in the retrieved literature excerpts; must be curated separately.
• NT2 biology and biomarkers: evidence in this run supports heterogeneity and possible overlap subgroups (intermediate orexin), but a definitive mechanism is not established here. (hamdan2024high‐resolutionhlasequencing pages 3-3, hamdan2024high‐resolutionhlasequencing pages 1-2)
• Autoantibodies: HCRTR2 autoantibodies were not supported as disease-specific in the 2024 cohort study. (hamdan2024high‐resolutionhlasequencing pages 6-6)

References (URLs and publication dates)

Primary sources used (examples; see citations inline): * Baldini V. et al. Pediatric Narcolepsy Type 1: A State-of-the-Art Review. Clinical and Translational Neuroscience. 2024-06. https://doi.org/10.3390/ctn8030025 (baldini2024pediatricnarcolepsytype pages 1-2) * Xu W. et al. The Role of T Cells in the Pathogenesis of Narcolepsy Type 1. Int J Mol Sci. 2024-11. https://doi.org/10.3390/ijms252211914 (xu2024theroleof pages 1-2) * Hamdan S. et al. High-resolution HLA sequencing and hypocretin receptor 2 autoantibodies. Int J Immunogenet. 2024-06. https://doi.org/10.1111/iji.12688 (hamdan2024high‐resolutionhlasequencing pages 1-2) * Mitsukawa K. et al. TAK-861 OX2R agonist preclinical study. Scientific Reports. 2024-09. https://doi.org/10.1038/s41598-024-70594-1 (mitsukawa2024tak861apotent pages 1-2) * Roy A. et al. RESTORE once-nightly oxybate preference. Sleep Medicine: X. 2024-12. https://doi.org/10.1016/j.sleepx.2024.100122 (roy2024restoreoncenightlyoxybate pages 1-2) * Zhou X. et al. FAERS pharmacovigilance analysis. Front Pharmacol. 2024-11. https://doi.org/10.3389/fphar.2024.1415918 (zhou2024evaluationofpitolisant pages 1-2) * Mignot E. et al. CSF hypocretin measurement diagnostic performance. Archives of Neurology. 2002-10. https://doi.org/10.1001/archneur.59.10.1553 (mignot2002theroleof pages 5-6)

References

1. (biscarini2025narcolepsyandrapid pages 1-2): Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, and Yves Dauvilliers. Narcolepsy and rapid eye movement sleep. Journal of Sleep Research, Jul 2025. URL: https://doi.org/10.1111/jsr.14277, doi:10.1111/jsr.14277. This article has 14 citations and is from a peer-reviewed journal.

2. (xu2025acomprehensivereview pages 1-2): Qinglin Xu, Yigang Chen, Tiantian Wang, Qiongbin Zhu, Jiahui Xu, and Lisan Zhang. A comprehensive review of current and emerging treatments for narcolepsy type 1. Journal of Clinical Medicine, 14:8444, Nov 2025. URL: https://doi.org/10.3390/jcm14238444, doi:10.3390/jcm14238444. This article has 1 citations.

3. (ariascarrion2026narcolepsyasan pages 3-4): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.

4. (mignot2002theroleof pages 5-6): Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, and Seiji Nishino. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of neurology, 59 10:1553-62, Oct 2002. URL: https://doi.org/10.1001/archneur.59.10.1553, doi:10.1001/archneur.59.10.1553. This article has 1400 citations.

5. (baldini2024pediatricnarcolepsytype pages 1-2): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

6. (zhou2024evaluationofpitolisant pages 1-2): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.

7. (ariascarrion2026narcolepsyasan pages 2-3): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.

8. (ariascarrion2026narcolepsyasan pages 5-6): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.

9. (xu2024theroleof pages 1-2): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.

10. (hamdan2024high‐resolutionhlasequencing pages 1-2): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.

11. (hamdan2024high‐resolutionhlasequencing pages 3-3): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.

12. (hamdan2024high‐resolutionhlasequencing pages 4-5): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.

13. (xu2024theroleof pages 2-3): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.

14. (xu2024theroleof pages 3-5): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.

15. (xu2024theroleof pages 7-8): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.

16. (baldini2024pediatricnarcolepsytype pages 2-4): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

17. (biscarini2025narcolepsyandrapid pages 5-6): Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, and Yves Dauvilliers. Narcolepsy and rapid eye movement sleep. Journal of Sleep Research, Jul 2025. URL: https://doi.org/10.1111/jsr.14277, doi:10.1111/jsr.14277. This article has 14 citations and is from a peer-reviewed journal.

18. (mignot2002theroleof pages 8-9): Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, and Seiji Nishino. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Archives of neurology, 59 10:1553-62, Oct 2002. URL: https://doi.org/10.1001/archneur.59.10.1553, doi:10.1001/archneur.59.10.1553. This article has 1400 citations.

19. (hamdan2024high‐resolutionhlasequencing pages 6-6): Samia Hamdan, Pontus Wasling, and Alexander Lind. High‐resolution hla sequencing and hypocretin receptor 2 autoantibodies in narcolepsy type 1 and type 2. International Journal of Immunogenetics, 51:310-318, Jun 2024. URL: https://doi.org/10.1111/iji.12688, doi:10.1111/iji.12688. This article has 1 citations and is from a peer-reviewed journal.

20. (xu2024theroleof pages 14-15): Wenqi Xu, Wenting Ding, Yu Zhang, Shuanshuan Wang, Xianyu Yan, Yirui Xu, Xiaoying Zhi, and Rongzeng Liu. The role of t cells in the pathogenesis of narcolepsy type 1: a narrative review. International Journal of Molecular Sciences, 25:11914, Nov 2024. URL: https://doi.org/10.3390/ijms252211914, doi:10.3390/ijms252211914. This article has 4 citations.

21. (ariascarrion2026narcolepsyasan pages 7-8): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.

22. (xu2025acomprehensivereview pages 9-11): Qinglin Xu, Yigang Chen, Tiantian Wang, Qiongbin Zhu, Jiahui Xu, and Lisan Zhang. A comprehensive review of current and emerging treatments for narcolepsy type 1. Journal of Clinical Medicine, 14:8444, Nov 2025. URL: https://doi.org/10.3390/jcm14238444, doi:10.3390/jcm14238444. This article has 1 citations.

23. (mitsukawa2024tak861apotent pages 2-3): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.

24. (baldini2024pediatricnarcolepsytype media 3ad4bd72): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

25. (baldini2024pediatricnarcolepsytype pages 8-9): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

26. (ariascarrion2026narcolepsyasan pages 21-22): Oscar Arias-Carrión, Emmanuel Ortega-Robles, Patricia Romano, and Carlos Pineda. Narcolepsy as an immune-associated hypothalamic encephalopathy: orexin dysfunction and implications for precision sleep medicine. Frontiers in Psychiatry, Apr 2026. URL: https://doi.org/10.3389/fpsyt.2026.1799520, doi:10.3389/fpsyt.2026.1799520. This article has 0 citations.

27. (baldini2024pediatricnarcolepsytype pages 9-11): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

28. (baldini2024pediatricnarcolepsytype pages 11-13): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

29. (roy2024restoreoncenightlyoxybate pages 1-2): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.

30. (roy2024restoreoncenightlyoxybate pages 2-3): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.

31. (mitsukawa2024tak861apotent pages 1-2): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.

32. (mitsukawa2024tak861apotent pages 3-4): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.

33. (mitsukawa2024tak861apotent pages 10-11): Kayo Mitsukawa, Michiko Terada, Ryuji Yamada, Taku Monjo, Tetsuaki Hiyoshi, Masanori Nakakariya, Yuichi Kajita, Tatsuya Ando, Tatsuki Koike, and Haruhide Kimura. Tak-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-70594-1, doi:10.1038/s41598-024-70594-1. This article has 21 citations and is from a peer-reviewed journal.

34. (zhou2024evaluationofpitolisant pages 8-9): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.

35. (baldini2024pediatricnarcolepsytype pages 14-15): Valentina Baldini, Francesco Biscarini, Giorgia Varallo, Fabio Pizza, and Giuseppe Plazzi. Pediatric narcolepsy type 1: a state-of-the-art review. Clinical and Translational Neuroscience, 8:25, Jun 2024. URL: https://doi.org/10.3390/ctn8030025, doi:10.3390/ctn8030025. This article has 4 citations.

36. (roy2024restoreoncenightlyoxybate pages 4-5): Asim Roy, Thomas Stern, John Harsh, J. Douglas Hudson, Akinyemi O. Ajayi, Bruce C. Corser, Emmanuel Mignot, Adrian Santamaria, Anne Marie Morse, Brian Abaluck, Sally Ibrahim, Paula K. Schweitzer, Katie Lancaster, Jordan Dubow, and Jennifer Gudeman. Restore: once-nightly oxybate dosing preference and nocturnal experience with twice-nightly oxybates. Sleep Medicine: X, 8:100122, Dec 2024. URL: https://doi.org/10.1016/j.sleepx.2024.100122, doi:10.1016/j.sleepx.2024.100122. This article has 9 citations.

37. (zhou2024evaluationofpitolisant pages 3-4): Xiaodan Zhou, Jia Chen, Bangtian Xu, and Li Chen. Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the faers database. Frontiers in Pharmacology, Nov 2024. URL: https://doi.org/10.3389/fphar.2024.1415918, doi:10.3389/fphar.2024.1415918. This article has 4 citations.